1-苯并噻吩-5-甲醇 | 20532-34-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 中文名称: 1-苯并噻吩-5-甲醇
• 英文名称: 5-(hydroxymethyl)benzothiophene
• 英文别名: 5-hydroxymethylbenzothiophene；benzo[b]thiophen-5-ylmethanol；1-benzothiophen-5-ylmethanol；benzo[b]thiophen-5-yl-methanol；5-hydroxymethylbenzo[b]thiophene；5-Hydroxymethyl-benzothiophen
• CAS: 20532-34-7
• 化学式: C₉H₈OS
• mdl: MFCD04972640
• 分子量: 164.228
• InChiKey: JSYSQUAJOCDMJW-UHFFFAOYSA-N

物化性质

• 熔点：
  91 °C
• 沸点：
  324.0±17.0 °C(Predicted)
• 密度：
  1.294±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  48.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090
• 安全说明：
  S24/25
• 储存条件：
  室温

SDS

Name:	1-Benzothiophen-5-ylmethanol 97% Material Safety Data Sheet
Synonym:
CAS:	20532-34-7

Section 1 - Chemical Product MSDS Name:1-Benzothiophen-5-ylmethanol 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
20532-34-7	1-Benzothiophen-5-ylmethanol	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 20532-34-7: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 93 - 94 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H8OS
Molecular Weight: 164.23

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Not available.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 20532-34-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-Benzothiophen-5-ylmethanol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 20532-34-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 20532-34-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 20532-34-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-苯并噻吩-5-甲醇 在 四溴化碳 、 三苯基膦 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以93%的产率得到5-bromomethyl-benzo[b]thiophene
  参考文献：
  名称：

  幽门螺杆菌II型脱氢喹啉酶的新型纳摩尔竞争抑制剂的合成和生物学评价。具有基本残基的芳香族部分作用的结构细节‡

  摘要：

  iki草酸途径对于许多病原体是必不可少的，但是在哺乳动物中是不存在的。因此，其途径中的酶是开发新型抗生素的合适靶标。脱氢喹啉酶是该途径的第三个酶，催化3-脱氢奎宁酸的可逆脱水形成3-脱氢shi草酸。在这里，我们提出了对幽门螺杆菌II型脱氢喹啉酶具有高亲和力和有效抑制特性的新型抑制剂的合成。幽门螺杆菌的结构与最有效的抑制剂配合使用的II型脱氢喹啉酶表明，芳香族官能团通过π堆积与催化的Tyr22相互作用，从而将Arg17侧链（对催化至关重要）从活性位点排出。因此，该结构解释了抑制剂的有利特性，并将有助于设计改良的抗生素。

  DOI：

  10.1021/jm9010466
• 作为产物：
  描述：

  5-溴苯并[b]噻吩 在 lithium aluminium tetrahydride 、 四(三苯基膦)钯 、 水 、 lithium hydroxide 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 1-苯并噻吩-5-甲醇
  参考文献：
  名称：

  GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS

  摘要：

  本公开提供了激活Wnt/β-连环蛋白信号通路并因此治疗或预防与信号转导相关的疾病的γ-二酮或其类似物；这些疾病包括骨质疏松症和骨关节病；骨发育不全、骨缺陷、骨折、牙周病、耳硬化症、伤口愈合、颅颌面缺陷、溶骨性骨病、创伤性脑损伤或脊柱损伤、与中枢神经系统分化和发育相关的脑萎缩/神经系统疾病，包括帕金森病、中风、缺血性脑疾病、癫痫、阿尔茨海默病、抑郁症、躁郁症、精神分裂症；耳部疾病如耳蜗毛细胞丧失；眼部疾病如老年性黄斑变性、糖尿病性黄斑水肿或视网膜色素变性以及与干细胞分化和生长相关的疾病，如脱发、造血相关疾病和组织再生相关疾病。

  公开号：

  US20140243349A1

文献信息

• GPR40 AGONISTS IN ANTI-DIABETIC DRUG COMBINATIONS
  申请人：Janssen Pharmaceutica NV

  公开号：US20170290800A1

  公开（公告）日：2017-10-12

  Disclosed are compositions comprising (a) a GPR40 agonist and (b) an SGLT2 inhibitor, and methods for treating of disorders that are affected by the modulation of the GPR40 receptor and SGLT2 transporter. Such GPR40 compounds are represented by Formula (I) as follows: wherein ring W, R 1 , R 2 , R 3 , R 5 , R 6 , A, and Z, are defined herein.

  本文披露了包含（a）GPR40激动剂和（b）SGLT2抑制剂的组合物，以及治疗受GPR40受体和SGLT2转运蛋白调节影响的疾病的方法。这些GPR40化合物由以下式（I）表示： 其中环W，R1，R2，R3，R5，R6，A和Z在此处被定义。
• SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES
  申请人：Janssen Pharmaceutica NV

  公开号：US20170291908A1

  公开（公告）日：2017-10-12

  Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein U 1 , U 2 , U 3 , R 1 , R 2 , Z, and W are defined herein.

  揭示了一种通过调节GPR40受体来治疗受影响疾病的化合物、组合物和方法。这些化合物由以下式（I）表示： 其中U1、U2、U3、R1、R2、Z和W在此处定义。
• [EN] SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES<br/>[FR] DÉRIVÉS DE BENZOTHIAZOLE SUBSTITUÉS UTILISÉS EN TANT QU'AGONISTES DE GPR40 POUR LE TRAITEMENT DU DIABÈTE DE TYPE II
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2016057731A1

  公开（公告）日：2016-04-14

  Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) wherein R1, R2, R3, R5, R6, W, and A are defined herein.

  揭示了一种通过调节GPR40受体来治疗受影响疾病的化合物、组合物和方法。这些化合物由式（I）所代表，其中R1、R2、R3、R5、R6、W和A在此处被定义。
• Substrate Fragmentation for the Design of<i>M. tuberculosis</i>CYP121 Inhibitors
  作者：Madeline E. Kavanagh、Janine L. Gray、Sophie H. Gilbert、Anthony G. Coyne、Kirsty J. McLean、Holly J. Davis、Andrew W. Munro、Chris Abell

  DOI：10.1002/cmdc.201600248

  日期：2016.9.6

  the structures of CYP121 substrates. The resulting inhibitors have low micromolar affinity, good predicted physicochemical properties and selectivity for CYP121 over other Mtb P450s. Spectroscopic characterisation of the inhibitors' binding mode provides insight into the effect of weak nitrogen-donor ligands on the P450 heme, an improved understanding of factors governing CYP121-ligand recognition and

  必需的结核分枝杆菌（Mtb）酶CYP121的环二肽底物被解构成其组成片段并针对该酶进行筛选。鉴定了许多命中，其中之一表现出意想不到的抑制剂样结合模式。阐明了抑制药效基团，并通过以CYP121底物的结构为指导的合成加工，迅速提高了片段结合亲和力。所得抑制剂与其他Mtb P450相比，具有较低的微摩尔亲和力，良好的预测理化性质和对CYP121的选择性。抑制剂结合模式的光谱表征可深入了解弱氮供体配体对P450血红素的影响，
• COMPETITIVE INHIBITORS OF TYPE II DEHYDROQUINASE ENZYME
  申请人：González Bello Cóncepcion

  公开号：US20110313032A1

  公开（公告）日：2011-12-22

  The present invention is directed to a compound of formula (I), its diastereoisomers, its enantiomers or its pharmaceutically acceptable salts or solvates, formula (I), to procedures of obtaining the same, to intermediates thereof, and use as competitive inhibitors of the third enzyme of the shikimic acid pathway, the type II dehydroquinase.

  本发明涉及一种化合物，其化学式为（I），其对映异构体，其对映体或其药学上可接受的盐或溶剂，化学式（I），以及获得该化合物的方法，其中间体，以及用作芪酸途径第三酶的竞争性抑制剂，即Ⅱ型脱氢奎尼酸酶。